OverviewSuggest Edit

Athenex is a biopharmaceutical company dedicated to the discovery and commercialization of therapies for the treatment of cancer. It operates medical technology innovation centers and a manufacturing supply chain. The company delivers proprietary medical technologies, including small molecule, biologic, and cellular therapies.
TypePublic
Founded2003
HQBuffalo, NY, US
Websiteathenex.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2018)575
Job Openings19
Revenue (FY, 2020)$144.4 M(+43%)
Share Price (Nov 2021)$2.1
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Athenex

Johnson Y.n. Lau

Johnson Y.n. Lau

Chief Executive Officer and Board Chairman, Director
Rudolf Kwan

Rudolf Kwan

Chief Medical Officer
Kim Campbell

Kim Campbell

Lead Independent Director
Simon Pedder

Simon Pedder

Chief Business and Strategy Officer, Proprietary Products
Stephanie Davis

Stephanie Davis

Director
Jordan Kanfer

Jordan Kanfer

Director
Show more

Athenex Office Locations

Athenex has offices in Buffalo, Clarence, Cranford, Houston and in 3 other locations
Buffalo, NY, US (HQ)
Conventus, 1001 Main St #600
Clarence, NY, US
11342 Main St
Cranford, NJ, US
20 Commerce Dr #100
Houston, TX, US
6200 Savoy Dr #1200
Schaumburg, IL, US
10 N Martingale Rd #230
Guatemala, GT
4A Avenida 14-21
Show all (11)

Athenex Financials and Metrics

Athenex Revenue

Embed Graph
View revenue for all periods
Athenex's revenue was reported to be $144.39 m in FY, 2020
USD

Revenue (Q1, 2021)

41.0m

Gross profit (Q1, 2021)

24.6m

Gross profit margin (Q1, 2021), %

60%

Net income (Q1, 2021)

(25.6m)

EBIT (Q1, 2021)

(20.6m)

Market capitalization (12-Nov-2021)

227.4m

Closing stock price (12-Nov-2021)

2.1

Cash (31-Mar-2021)

48.0m

EV

190.4m
Athenex's current market capitalization is $227.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

38.0m89.1m101.2m144.4m

Cost of goods sold

25.1m47.0m69.6m95.4m

Gross profit

12.9m42.1m31.6m49.0m

Gross profit Margin, %

34%47%31%34%
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

4.6m14.0m37.8m11.6m18.4m25.3m22.2m19.4m46.9m40.2m35.5m41.0m

Cost of goods sold

4.1m8.1m11.3m9.4m12.0m19.9m16.9m17.1m19.6m33.0m24.5m16.4m

Gross profit

458.0k5.9m26.5m2.1m6.5m5.4m5.3m2.3m27.4m7.2m11.0m24.6m

Gross profit Margin, %

10%42%70%18%35%21%24%12%58%18%31%60%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

39.3m49.8m127.7m69.6m

Accounts Receivable

8.5m13.0m16.7m23.6m

Prepaid Expenses

7.7m21.7m20.8m14.8m

Inventories

16.6m28.8m32.6m28.8m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(131.4m)(128.7m)(125.5m)(148.4m)

Depreciation and Amortization

3.7m3.3m3.8m4.5m

Inventories

(12.3m)(12.2m)(3.8m)3.8m

Accounts Payable

18.8m3.5m19.3m(13.1m)
USDQ2, 2017

Financial Leverage

1.3 x
Show all financial metrics

Athenex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Athenex Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Athenex Online and Social Media Presence

Embed Graph

Athenex News and Updates

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021

Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board C…

Athenex 將於 Evercore ISI 第 4 屆年度 HealthCONx 會議上發表演說

紐約水牛城, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) 作為一家全球生物製藥公司,致力發現與開發治療癌症及相關疾病的新療法及將其商業化,今天宣佈行政總裁兼董事會主席劉耀南 (Johnson Lau) 與企業發展高級董事 Daniel Lang 將在 11 月 30 日(星期二)下午 3:55(美國東部時間)舉行的 Evercore ISI 第 4 屆年度 HealthCONx 會議上發表演說。

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies

Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR).

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021

BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporat…
Show more

Athenex Blogs

Athenex Provides Third Quarter 2021 Corporate and Financial Update

Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M , up 9% year-over-year Company now expects full year product sales revenue in 2021 to decrease

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021 Content Import Fri, 10/22/2021 - 16:05 Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021 October 22, 2021 This rel…

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program Content Import Fri, 06/04/2021 - 09:06 Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program June 4, 2021 This relea…

Athenex to Provide Corporate and Financial Update for the First Quarter 2021 on May 6, 2021

BUFFALO, N.Y. , April 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a

CEO Dr. Johnson Lau Recuperating from COVID at Home

BUFFALO, N.Y. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman,

CEO Dr. Johnson Lau Contracts COVID-19

BUFFALO, N.Y. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr.
Show more

Athenex Frequently Asked Questions

  • When was Athenex founded?

    Athenex was founded in 2003.

  • Who are Athenex key executives?

    Athenex's key executives are Johnson Y.n. Lau, Rudolf Kwan and Kim Campbell.

  • How many employees does Athenex have?

    Athenex has 575 employees.

  • What is Athenex revenue?

    Latest Athenex annual revenue is $144.4 m.

  • What is Athenex revenue per employee?

    Latest Athenex revenue per employee is $251.1 k.

  • Who are Athenex competitors?

    Competitors of Athenex include Precision Medicines, ImmVira and NOXXON Pharma.

  • Where is Athenex headquarters?

    Athenex headquarters is located at Conventus, 1001 Main St #600, Buffalo.

  • Where are Athenex offices?

    Athenex has offices in Buffalo, Clarence, Cranford, Houston and in 3 other locations.

  • How many offices does Athenex have?

    Athenex has 11 offices.